Categories: News

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to implant FDA-approved novel defibrillation lead

The new technology is the world’s smallest, catheter-delivered defibrillation lead

- Advertisement -

AUSTIN, Texas, Feb. 2, 2026 /PRNewswire/ — Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center recently became the first in the nation to implant an FDA-approved novel defibrillation lead—a specialized, insulated wire that connects to an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT-Ds) device to the heart and corrects abnormal rhythm. The defibrillation lead is the world’s smallest, catheter-delivered defibrillation lead, which allows for precise delivery and placement in the right ventricle.

- Advertisement -

The first procedure was performed by Robert Canby, M.D., and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologists at TCAI, on Jan. 7. Dr. Canby also participated in the trial that led to FDA approval.

- Advertisement -

“When treating patients, safety and efficacy are paramount, and this novel technology allows us to achieve both with greater precision,” said Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI. “This milestone is a testament to the Texas Cardiac Arrhythmia Institute’s continued pursuit of innovation that will improve outcomes and access to life-saving care.”

- Advertisement -

A lead senses the heartbeat and transmits signals to the implanted device, which then delivers therapy to correct or interrupt abnormally fast rhythms—called arrhythmias—that can result in sudden cardiac arrest. Existing defibrillation leads are larger in diameter, increasing the potential for future complications.

- Advertisement -

According to the Journal of the American Heart Association, an estimated 12.1 million people in the U.S. are expected to have atrial fibrillation—the most common arrhythmia—by 2030.

- Advertisement -

TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of esteemed cardiac electrophysiologists—led by Dr. Natale, a world-renowned expert in the field—perform a high volume of the most complex electrophysiology procedures.

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/texas-cardiac-arrhythmia-institute-at-st-davids-medical-center-first-in-us-to-implant-fda-approved-novel-defibrillation-lead-302675495.html

- Advertisement -

Recent Posts

Shiny Smile Veneers 2026: Claims Examined, Pricing Verified & What Consumers Should Confirm Before Buying

New York City, NY, March 14, 2026 (GLOBE NEWSWIRE) -- For anyone who has been…

1 hour ago

Lean Drops Announces USA & Canada Debut: Introducing LeanDrops Weight Management Liquid Formula

New York City, NY, March 14, 2026 (GLOBE NEWSWIRE) -- Lean Drops, an innovative liquid…

1 hour ago

Sugar Harmony (2026 CONSUMER REPORT): Tainted Supplement Warning Issued as “Glucose Reset Ritual” Goes Viral

New York City, NY, March 14, 2026 (GLOBE NEWSWIRE) -- Sugar Harmony: SugarHarmony Research has…

1 hour ago

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

March 14, 2026 10:15 ET  | Source: Senseonics Holdings, Inc. New data shows positive real-world…

4 hours ago

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,”…

4 hours ago

AgelessRx 2026: Longevity Telehealth Platform Overview Treatments, Pricing, Compounded Medications, and What Prospective Patients Should Know

Ann Arbor, MI, March 13, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational…

4 hours ago